Updated

FDA advisers are evaluating Grail's Galleri test, which screens for 50 different cancers from a single blood draw. A major clinical study failed to demonstrate the test's ability to detect later-stage cancers, raising questions about its clinical utility and the likelihood of Medicare coverage. The review comes as liquid biopsy and early cancer detection have become increasingly important areas of focus for both regulators and healthcare investors.